Syneron Medical (ELOS) Receives FDA Approval for Plus
Tweet
Share
E-mailGet Alerts ELOS Hot Sheet
Join SI Premium – FREE
Syneron Medical Ltd. (NASDAQ: ELOS) has received United States Food and Drug Administration (FDA) clearance for elos Plus™, a next generation multi-platform system featuring the Company's proprietary elos technology. The FDA clearance for elos Plus™ follows on the recent international launch in Europe and Asia.
The new elos Plus™ leverages the Company's proprietary elos® technology of optical energy and bi-polar radiofrequency to provide safe and efficacious treatments.
The new elos Plus™ leverages the Company's proprietary elos® technology of optical energy and bi-polar radiofrequency to provide safe and efficacious treatments.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab
- Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287
- Ascendis Pharma (ASND) Announces UK Approval of YORVIPATH
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
